Suchen und filtern

Gefundene Studien

GOBLET A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab AIO-KRK-0320ass · In Rekrutierung Studie anzeigen

ATOMIC Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair AIO-KRK-0317 · In Rekrutierung Studie anzeigen

FIRE-7 Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7) AIO-KRK-0120 · In Rekrutierung Studie anzeigen

FIRE-8 Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab
as first-line treatment of metastatic colorectal cancer AIO-KRK/YMO-0519 · In Rekrutierung Studie anzeigen

PIONEER Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq in local squamous cell carcinoma of the head and neck – an imCORE Study AIO-KHT-0220/ass · In Rekrutierung Studie anzeigen

ABC-HCC Trial A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma AIO-HEP-0321/ass · In Rekrutierung Studie anzeigen

ADVANCE A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements - ADVANCE AIO-HEP-0221/ass · In Rekrutierung Studie anzeigen

IRITACE Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC). (IRITACE) AIO-HEP-0220/ass · In Rekrutierung Studie anzeigen

SOLARIS A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy - SOLARIS AIO-HEP-0121/ass · In Rekrutierung Studie anzeigen

TRADEhypo Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) AIO-YMO/TRK-0319 · In Rekrutierung Studie anzeigen